Xal may be part of symptomatic management for various bacterial infections throughout the body. It is considered relevant for use in conditions such as those affecting the urinary tract, lower respiratory tract, and skin.

Main Uses and Benefits of Xal

Xal is commonly used to address the bacterial source of acute illnesses in specific domains. The medicine may assist with the process of recovery in conditions characterized by periods of heightened symptoms.

“Xal generally supports the easing of the overall symptom burden associated with acute infectious phases.”

The medication may assist in addressing symptom clusters that become intense or disruptive. These may include symptoms related to systemic imbalance, such as fever and chills, and symptoms linked to organ-specific functional stress.

Applied in clinical settings that involve acute symptom patterns, the medication may assist with maintaining functional stability and supports patients during episodes of heightened discomfort, providing supportive relief when symptoms interfere with routine activities. It is commonly used in contexts involving heightened systemic burden.

Quick Fact: Relief for Acute Discomfort Xal is considered relevant in situations involving acute or disruptive symptom patterns by supporting improved day-to-day comfort during symptomatic periods.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility for Xal (Crizotinib) Based on Regulatory Documentation

Xal is authorized for use only in patients whose tumors are confirmed to be Anaplastic Lymphoma Kinase (ALK)-positive or ROS1-positive, as detected by an officially approved diagnostic test.

Populations for Whom Use is Allowed or Restricted

• Adults may use Xal for ALK- or ROS1-positive metastatic non-small cell lung cancer (NSCLC) and ALK-positive inflammatory myofibroblastic tumor (IMT).
• Pediatric patients 1 year of age and older and young adults may use it for ALK-positive anaplastic large cell lymphoma (ALCL) and ALK-positive IMT. Safety and effectiveness have not been established in older adults with ALK-positive ALCL.

Contraindications and Special Considerations

• Contraindications: Use is prohibited in patients with a known hypersensitivity to crizotinib or any excipients. It is also contraindicated in patients with severe hepatic impairment (liver function problems) per European regulatory documents.
• Pregnancy and Lactation: Xal is not recommended for use during pregnancy as it can cause fetal harm. Females of reproductive potential must use effective contraception during treatment and for 45 days after the final dose; males with female partners must use condoms for 90 days after the last dose. Breastfeeding is not recommended during treatment and for 45 days after the last dose.

Xal Interactions with other medicines and products

Interaction Category	Specific Entity / Interaction Description
Contraindicated Combinations	Co-administration with Tizanidine is prohibited due to the risk of increased systemic exposure of Tizanidine. Combination with Class IA and Class III Antiarrhythmics is also prohibited due to the potential for additive QT prolongation.
Pharmacokinetic Interactions	The Ofloxacin component acts as a moderate inhibitor of Cytochrome P450 1A2 (CYP1A2). This interaction increases the plasma concentrations of co-administered CYP1A2 substrates, such as Theophylline or Caffeine.
Timing / Separation Rules	Cation-containing agents, including Antacids (aluminum, magnesium), Sucralfate, and supplements containing Iron or Zinc, significantly reduce Xal’s oral absorption. Administration of these products must be separated by a mandatory window of at least two hours before or two hours after Xal administration.
Pharmacodynamic Risk	Co-administration with systemic Corticosteroids carries a documented increased risk of tendinitis and tendon rupture. Concurrent use with high doses of Non-Steroidal Anti-inflammatory Drugs (NSAIDs) may increase the risk of CNS stimulation.
Exposure Modification	Co-administration with Probenecid reduces the renal clearance of Ofloxacin, officially increasing its systemic exposure. Xal also formally enhances the anticoagulant effect of Warfarin, resulting in an increase in INR.

The regulatory documents establish Xal’s interaction profile based on three core patterns: formal contraindications with specific antiarrhythmics and Tizanidine; physical restrictions due to chelation by cation-containing agents that mandate specific timing rules; and pharmacokinetic restrictions involving CYP1A2 inhibition and interference with renal clearance. This structure formally defines the substances and conditions under which interaction effects, such as increased drug exposure or heightened organ risk, are documented by regulatory authorities.

Targeted Inhibition of Bacterial Genetic Maintenance

The core anti-infective mechanism is exerted by Ofloxacin, which operates by binding to and stabilizing the complexes formed by the critical bacterial enzymes DNA Gyrase and DNA Topoisomerase IV with the bacterial DNA. This interaction halts the re-ligation of cleaved DNA strands, leading to double-strand breaks and irreversible DNA damage. The resulting cascade induces a bactericidal effect, causing pathogen cell death by preventing its ability to replicate or repair its genetic material.

---

Supportive Regulation of Systemic Homeostasis

The combination of electrolytes and metabolic regulators (Ammonium Chloride, Potassium Chloride, Calcium Formate, Glutamic Acid) provides a complementary mechanism focused on sustaining systemic homeostasis. These components supply essential ions ( K^+, Ca^2+) crucial for stabilizing cellular membrane potentials in nerve and muscle tissues. Furthermore, they support renal mechanisms for acid-base balance by facilitating the net excretion of acid equivalents, which contributes to the stability of systemic pH.

The usage of Xal is strictly governed by regulatory documents that detail its administration parameters and schedule for systemic therapy. Xal is approved solely for Intravenous (IV) Infusion and must be administered within a controlled clinical environment, such as a hospital or supervised clinic setting. This method is mandated by its composition as a sterile solution intended to deliver both the antibiotic and supportive electrolyte components throughout the body.

The standard adult dosing schedule typically starts with an initial dose of 400 mg of Ofloxacin (the main anti-infective component). The maintenance dose is generally set within a range of 400 mg to 800 mg per day, with the absolute maximum daily dose not to exceed 800 mg. This regimen is administered either once daily or divided into two doses (q12h). The overall course of therapy typically lasts between 7 and 14 days, although continuation may be directed for 48 hours after clinical signs have resolved.

A critical instruction for administration is the rate of infusion. Official labeling requires that the entire dose be infused slowly over a period of at least 60 minutes and must never be administered as a rapid bolus injection. Xal must not be mixed with other medications in the same IV line due to potential incompatibilities with its complex electrolyte formulation. Furthermore, dose reduction is a formal requirement for patients with impaired kidney function (creatinine clearance less than 50 mL/min), a mandatory adjustment stipulated in the official prescribing information.

Evidence for Anti-infective Use in Bacterial Infections

The research base for Xal focuses on the anti-infective component, evaluated in Randomized Controlled Trials (RCTs) against other treatments for infections in the urinary tract, lower respiratory tract, and skin. These studies were conducted during periods of increased symptom activity to measure rates of microbiological clearance and track the evolution of clinical signs. Findings describe patterns observed in the studies, in a manner consistent with the activity profile evaluated for the quinolone class of antibiotics. The results apply only to the populations studied.

Research on Supportive and Metabolic Effects

Studies have explored the role of the solution's supportive components (electrolytes and metabolic regulators) in patients dealing with acute infection, often utilizing observational settings. Research examined outcomes related to systemic imbalance by monitoring physiological strain or stress and systemic biomarkers, such as changes in electrolyte concentrations. Limited information is available from high-quality comparative trials to establish if the fixed Xal solution was associated with a different outcome compared to standard supportive measures administered separately.

Research Gaps and Remaining Uncertainties

Long-term effects are not fully established because follow-up durations mainly covered the acute treatment window (typically 7 to 14 days). Data characterizing the durability of responses or the risk of recurrence over extended periods is limited. Furthermore, the comparative evidence is lacking from high-quality randomized trials that would clarify the specific contribution of using the fixed combination solution instead of administering the antibiotic and standard supportive fluid/electrolyte therapy separately. Research continues to examine outcomes in specific patient subgroups, such as older adult populations, where subgroup findings are uncertain.

Key Studies & References NIH MedlinePlus Drug Information (Quinolone Antibiotic Class Context)

Common questions about Xal (FAQ)

---

Q: Is Xal a generic medicine or is it only available under a brand name?

Xal is a specific combination product containing Ofloxacin. Ofloxacin is the main active ingredient and is available as a generic medicine under various brand names, and also available generically. The combination product, Xal, is the focus of the regulatory documents.

Q: If Xal works, how long does the effect usually last?

This question cannot be answered using the authoritative regulatory documents. Information characterizing the durability of the response or the risk of recurrence over extended periods is explicitly listed as limited in the official research summaries.

Q: Is Xal known to cause weight gain, or is that a common patient concern?

According to authoritative regulatory documents for the Ofloxacin component, weight gain is not listed as a common or serious adverse reaction. The officially documented side effects typically involve gastrointestinal and nervous system effects.

Q: Can Xal affect the way my birth control pills work?

Studies and official information indicate that the Ofloxacin component of Xal does not significantly interfere with the effectiveness of hormonal contraceptives, unlike some other classes of antibiotics. This information is based on general safety profiles of the drug class.

Q: Why does the official documentation mention that Xal has a 'half-life' of so many hours?

The half-life is a measure used in regulatory documents to describe how long it takes for the concentration of the drug in the blood to decrease by half. For the Ofloxacin component, the plasma half-life is typically stated to be in the range of 4 to 7.4 hours. This factual measure helps to inform the appropriate dosing schedule for the patient.

Q: Is Xal typically covered by most health insurance plans, or is it very expensive?

This question addresses cost and coverage, which is not addressed within the scope of regulatory or authoritative medical documents. Insurance coverage varies widely based on plan type, formulary status, and pharmacy, and is not a factor of the drug's official product information.

Q: What happens if I forget to take Xal on a regular schedule?

According to official patient information, if a dose is missed, the instruction is to take it as soon as it is remembered. If it is almost time for the next scheduled dose, the instruction is to skip the missed dose and continue the regular schedule, rather than taking a double dose.

Q: Does Xal interact with herbal supplements like St. John's Wort or melatonin?

This question cannot be answered using the authoritative regulatory documents. Official documents detail interactions with specific prescription and over-the-counter medicines, but do not provide specific interaction information for St. John's Wort or melatonin.

Q: Does Xal have a dependency or addiction risk described in official sources?

Regulatory documents indicate that Xal is not classified as a controlled substance by major regulatory bodies. It is not documented to have an official risk of dependency or addiction.

Q: Can men and women expect different side effects from taking Xal?

Pharmacokinetic studies for the Ofloxacin component show that maximum plasma concentrations may be higher in elderly females compared to elderly males, which may influence individual response. However, specific differences in common side effect reporting between genders are not routinely listed in official documents.

Q: Why is there a requirement to monitor specific lab tests while taking Xal?

Official documentation recommends monitoring specific lab tests for safety. For example, blood glucose should be monitored in diabetic patients due to a documented risk of hypoglycemia (low blood sugar). Additionally, coagulation tests may be monitored in patients taking blood thinners due to an increased risk of bleeding.

Q: Is Xal the same type of drug as a medicine that has 'Xal' in its name?

This question cannot be answered using the authoritative regulatory documents. Official documents focus solely on the chemical composition and established trade name of Xal and do not provide comparisons to other drugs with similar names.

Q: Why do some people stop taking Xal after a short time?

The treatment course is typically short (7 to 14 days) to clear the infection. Patients may stop early due to the occurrence of serious adverse reactions (such as tendon issues or severe nerve problems) that require immediate discontinuation, or by clinical decision if the infection resolves.

Q: What official warnings are listed for Xal about operating machinery or driving?

The official product information notes that Xal can cause side effects like dizziness, vertigo, or visual disturbances. Because these effects may impair the ability to drive or operate machinery, official documentation indicates that caution should be exercised regarding these activities.

Q: Does Xal interact with alcohol, and what are the general warnings?

Official documentation reports no formal prohibition against using alcohol with the Ofloxacin component. However, alcohol use may increase the risk of nervous system side effects such as dizziness or drowsiness. Official documentation does not provide a formal prohibition, but notes that alcohol use may increase the risk of these effects.

Q: What are the general rules for stopping Xal if my doctor recommends it?

Regulatory statements indicate that cessation should not be abrupt unless under medical supervision, even when symptoms improve. Stopping therapy early risks the infection returning or the development of antibiotic resistance.

Q: Does Xal affect blood pressure or blood sugar levels?

Official documentation reports that the Ofloxacin component can cause hypoglycemia (low blood sugar), particularly in diabetic patients using insulin or oral hypoglycemic agents. While not routinely listed for direct effects on blood pressure, cardiac risks like QT prolongation are documented.

Q: What is the official safety classification of Xal for the general public?

This question cannot be answered using the authoritative regulatory documents. The official documents classify Xal by its pharmacological class (Quinolone Antibiotic, Electrolyte/Metabolic Regulator) but do not assign a general public safety schedule or classification.

Q: Does Xal need to be taken at a specific time of day for the best effect?

The drug is typically given once daily or divided into two doses (every 12 hours). Official guidelines emphasize taking the dose around the same times every day to maintain a consistent level of medicine in the blood, which is important for the anti-infective action.

Q: What is the evidence theme regarding Xal's effectiveness in different ethnic groups?

This question cannot be answered using the authoritative regulatory documents. Research summaries confirm that studies continue to examine outcomes in specific patient subgroups, but official documentation does not specify findings or evidence themes regarding different ethnic groups.

Q: Are there any official reports of Xal being studied for new uses in the future?

This question cannot be answered using the authoritative regulatory documents. Official research overviews focus on the evidence for the drug's approved uses and do not typically detail reports on new, unapproved indications being studied.

Q: Is Xal a controlled substance or a restricted drug?

Xal is not designated as a controlled substance by the DEA or other major regulatory bodies. It is classified as a prescription medicine.

Q: What does the regulatory body documentation say about the purity of Xal?

Regulatory documentation confirms that Xal must meet strict manufacturing and quality control standards to ensure its purity, strength, and identity. This compliance with regulatory standards, such as Good Manufacturing Practice, is formally verified by the authorizing regulatory bodies.

How to Store and Dispose of Xal?

This section describes the mandatory storage and disposal conditions for Xal (Ofloxacin, Electrolyte/Metabolic Regulator Solution) as documented in official regulatory sources for its component classes.

---

Storage Conditions

Detail	Official Regulatory Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C), with permitted short-term excursions (15 C to 30 C).
Protection	Must be protected from light and stored away from heat and moisture. Keep from freezing.
Container	Keep the container tightly closed and stored in a dry, well-ventilated place.
Child Safety	Must be kept out of the reach of children.

---

Disposal Instructions

Unused or expired Xal must not be kept. The preferred method for disposal is through an authorized drug take-back program or using a pre-paid mail-back envelope. If household disposal is necessary, the medicine must be mixed with an undesirable substance, placed in a sealed container, and discarded in the trash. The product must not be emptied into drains.